This inventor holds 1 USPTO granted patent and 15 published patent applications and 5 EPO patents. Top assignee: Nordic Bioscience A/s. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Nicholas Willumsen: Innovator in Cancer Detection
Introduction
Nicholas Willumsen is an inventor based in Gentofte, Denmark. He is currently associated with Nordic Bioscience A/S, where he focuses on developing innovative solutions for cancer detection. Despite having no granted patents to his name, his contributions to the field of immunoassays are noteworthy.
Latest Patent Applications
Nicholas Willumsen has been involved in several significant patent applications. One of his latest applications is for the "Collagen Type XXII Assay," which relates to immunoassays designed for detecting and monitoring cancer in patients. This invention includes monoclonal antibodies and immunoassay kits that facilitate the detection process. Another application is for an "Assay for Assessing Cancer," which describes methods for detecting and monitoring cancer by using a biofluid sample from a patient. This method involves a monoclonal antibody that specifically binds to a C-terminal epitope of type XXVIII collagen, allowing for the detection and quantification of binding in the sample.
Conclusion
Nicholas Willumsen is making strides in the field of cancer detection through his innovative patent applications. His work at Nordic Bioscience A/S highlights his commitment to advancing medical technology.